Atypical hemolytic uremic syndromeNews & Research
18 curated articles for Atypical hemolytic uremic syndrome — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Journal of medical case reports May 22, 2026
Severe leptospirosis complicated by atypical hemolytic uremic syndrome, myocarditis, and acute liver injury: a therapeutic challenge-a case report and review of the literature.
Severe leptospirosis, also known as Weil's disease, is a life-threatening zoonotic infection characterized by multi-organ dysfunction, including acute kidney injury and jaundice. We report this case due to its rarity and complex nature. This case report describes a 44-year-old previously healthy, Sr...
Why it matters: Recent peer-reviewed research on Atypical hemolytic uremic syndrome that may be relevant for patients and caregivers.
- Transplantation proceedings May 17, 2026
Possible Adenovirus Triggered Case of Atypical Hemolytic Uremic Syndrome in a Kidney Transplant Recipient: A Case Report and A Review of the Literature.
Atypical hemolytic uremic syndrome (aHUS) is a rare disorder of the alternative complement pathway characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. It has a genetic background or may be triggered by viral infections and certain medications, such as immun...
Why it matters: Recent peer-reviewed research on Atypical hemolytic uremic syndrome that may be relevant for patients and caregivers.
- Molecular biology reports May 14, 2026
A review of genetic and epigenetic biomarkers involved in the occurrence of atypical hemolytic uremic syndrome and its therapeutic strategies.
Atypical hemolytic uremic syndrome (aHUS) is a rare, chronic, and life-threatening thrombotic microangiopathy (TMA). The disease is most frequently linked to genetic or acquired dysregulation of the alternative complement pathway and affects both children and adults. The paucity of a gold standard f...
Why it matters: Recent peer-reviewed research on Atypical hemolytic uremic syndrome that may be relevant for patients and caregivers.
- Frontiers in medicine May 13, 2026
Atypical hemolytic uremic syndrome in a patient with thalassemia and a CFH gene mutation: a case report.
Atypical hemolytic uremic syndrome (aHUS) is a complement-associated thrombotic microangiopathy (TMA). Thalassemia is a hemolytic anemia triggered by defects in the beta-globin gene. Mutations in the complement factor H (CFH) gene are associated with the development of aHUS; however, CFH gene mutati...
Why it matters: Recent peer-reviewed research on Atypical hemolytic uremic syndrome that may be relevant for patients and caregivers.
- BMC nephrology Apr 16, 2026
Complement role in kidney disease: a comprehensive review and therapeutic innovations.
The complement system is a vital component of innate immunity, known for its role in pathogen defense. It has been increasingly recognized as a mediator of homeostatic clearance, tissue repair, and immune-metabolic crosstalk. In the kidney, unique anatomical and hemodynamic features predispose to ab...
Why it matters: Recent peer-reviewed research on Atypical hemolytic uremic syndrome that may be relevant for patients and caregivers.
- Kidney & blood pressure research Apr 10, 2026
New Anticomplement Drugs in Nephrology - Mechanism and Indication.
The complement system is a key component of innate immunity, critical for pathogen defense, inflammation, and immune regulation. Dysregulation or overactivation of complement pathways contributes to the pathogenesis of numerous kidney diseases, including atypical hemolytic uremic syndrome (aHUS), C3...
Why it matters: Recent peer-reviewed research on Atypical hemolytic uremic syndrome that may be relevant for patients and caregivers.
- Pediatric nephrology (Berlin, Germany) Mar 24, 2026
Recurrent pancreatitis and atypical hemolytic uremic syndrome (aHUS): an unusual presentation in childhood.
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by the classical triad of acute hemolytic anemia, thrombocytopenia, and kidney impairment. We report a 10-year-old boy with acute pancreatitis presenting simultaneously with atypical HUS (aHUS) with two such episodes occur...
Why it matters: Recent peer-reviewed research on Atypical hemolytic uremic syndrome that may be relevant for patients and caregivers.
- Blood advances Mar 13, 2026
Treatment of atypical hemolytic uremic syndrome and C3 glomerulopathy in mice by hepatic expression of factor D.
Atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) are diseases driven by dysregulation of the alternative pathway (AP) complement. Current treatments of these diseases involve the use of frequent and often large doses of monoclonal antibodies, peptide inhibitors, or chemical inhi...
Why it matters: Recent peer-reviewed research on Atypical hemolytic uremic syndrome that may be relevant for patients and caregivers.
- Clinical kidney journal Mar 13, 2026
Thrombotic microangiopathy after kidney transplantation: diagnosis and management strategies.
Thrombotic microangiopathy (TMA) is a pathological condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and ischemic organ dysfunction due to microvascular endothelial damage and thrombosis. It affects ∼0.8%-14% of kidney transplant recipients, and may manifest as e...
Why it matters: Recent peer-reviewed research on Atypical hemolytic uremic syndrome that may be relevant for patients and caregivers.
- Clinical journal of the American Society of Nephrology : CJASN Mar 13, 2026
Practical Considerations for Infection Prevention with the Clinical Use of Complement Inhibitors.
Overactivation of the complement system plays a role in the pathophysiology of several serious kidney diseases, such as IgA nephropathy, complement 3 glomerulopathy, atypical hemolytic uremic syndrome, and ANCA-associated vasculitis. A key focus of recent research has been developing complement inhi...
Why it matters: Recent peer-reviewed research on Atypical hemolytic uremic syndrome that may be relevant for patients and caregivers.
- Current opinion in pediatrics Mar 6, 2026
Updates in atypical hemolytic syndrome.
This review aims to summarize how scientific advances in complement biology have not only improved the diagnosis and management of aHUS but also continue to offer insights into the pathophysiology of complement-mediated disease that may be leveraged for future therapeutic developments. Updated infor...
Why it matters: Recent peer-reviewed research on Atypical hemolytic uremic syndrome that may be relevant for patients and caregivers.
- European journal of paediatric dentistry Mar 6, 2026
Bilateral root absence of permanent first molars: literature review and case report.
This case report and literature review aim to elucidate the rare occurrence of bilateral root absence in permanent first molars, emphasizing its clinical implications, diagnostic challenges, management, and possible association with systemic conditions. A unique case involving a 13-year-old male dia...
Why it matters: Recent peer-reviewed research on Atypical hemolytic uremic syndrome that may be relevant for patients and caregivers.
- Kidney international Feb 21, 2026
Modern challenges in infection prevention: encapsulated organisms in the era of novel complement inhibitors.
Complement inhibitors are now approved for use in atypical hemolytic uremic syndrome, IgA nephropathy, and C3 glomerulopathy. They are being studied widely in kidney disease, and more indications may soon arise. This review addresses an approach to preventing infectious complications, particularly e...
Why it matters: Recent peer-reviewed research on Atypical hemolytic uremic syndrome that may be relevant for patients and caregivers.
- Frontiers in medicine Feb 16, 2026
An unusual trilogy: a case of comorbid aHUS, Fabry disease, and hypertrophic cardiomyopathy.
A 7-year-old boy was admitted to the hospital for abdominal pain, vomiting, and edema. Examinations revealed microvascular hemolytic anemia, thrombocytopenia, acute kidney injury, and hypocomplementemia. He was diagnosed with atypical hemolytic uremic syndrome (aHUS), and treatment was initiated wit...
Why it matters: Recent peer-reviewed research on Atypical hemolytic uremic syndrome that may be relevant for patients and caregivers.
- The American journal of case reports Feb 10, 2026
Actinomycotic Cholecystitis and Pancreatitis: Report of an Unusual Case.
BACKGROUND Actinomycosis is an uncommon bacterial infection caused by the commensal organism Actinomyces spp., which can become pathogenic upon tissue injury or disruption of the mucosal barrier. While primarily recognized for its cervicofacial and abdominopelvic presentations, actinomycosis can als...
Why it matters: Recent peer-reviewed research on Atypical hemolytic uremic syndrome that may be relevant for patients and caregivers.
- Clinical case reports Feb 2, 2026
A Case of Severe Pre-Eclampsia Complicated by HELLP Syndrome and Extensive Hepatic Infarction.
Extensive hepatic infarction is a rare but potentially fatal complication of HELLP syndrome and is often difficult to recognize because of nonspecific clinical manifestations. A 34-year-old woman developed HELLP syndrome shortly after cesarean delivery for severe pre-eclampsia, presenting with oligu...
Why it matters: Recent peer-reviewed research on Atypical hemolytic uremic syndrome that may be relevant for patients and caregivers.
- Kidney international Jan 23, 2026
Severe hypertension with thrombotic microangiopathy: the need for pathogenically targeted treatments.
Malignant hypertension with acute kidney injury or acute kidney disease is a life-threatening condition requiring urgent antihypertensive treatment and which carries a serious risk of kidney function loss. The presence of thrombotic microangiopathy (microangiopathic hemolytic anemia and thrombocytop...
Why it matters: Recent peer-reviewed research on Atypical hemolytic uremic syndrome that may be relevant for patients and caregivers.
- Kidney international reports Jan 19, 2026
Antimeningococcal Protection in Patients Receiving Terminal Complement Inhibitors.
C5 inhibitor (C5i) therapy markedly increases susceptibility to invasive meningococcal disease (IMD) by blocking the terminal complement pathway essential for defense against Neisseria meningitidis. Vaccination is recommended for all recipients, yet breakthrough infections persist. Antibiotic prophy...
Why it matters: Recent peer-reviewed research on Atypical hemolytic uremic syndrome that may be relevant for patients and caregivers.
More on Atypical hemolytic uremic syndrome
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.